Infinium Pharmachem Ltd.

As of March 31, 2026, Infinium Pharmachem Ltd. carries a market capitalization of 3.00B, placing it among publicly traded companies globally. Its enterprise value stands at 3.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Infinium Pharmachem Ltd. has 15.58M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Infinium Pharmachem Ltd. maintains a current ratio of 3.84, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Infinium Pharmachem Ltd. recorded 18.33M in income tax expense.

As of the close on October 23, 2026, Infinium Pharmachem Ltd.'s stock has gained approximately 13.72% over the past 52 weeks. The 50-day moving average sits at 272.30, while the 200-day moving average is 226.90.

As of March 31, 2026, Infinium Pharmachem Ltd. holds 297.81M in cash and equivalents against 230.92M in total debt, resulting in a net debt position of 198.57M. Total book value stands at 1.21B, with working capital of 813.25M providing operational flexibility.

Infinium Pharmachem Ltd.'s most recent stock split took place on September 13, 2023 with a 1:2 split ratio.